CorMedix Inc. (CRMD): Price and Financial Metrics


CorMedix Inc. (CRMD)

Today's Latest Price: $5.20 USD

0.03 (-0.57%)

Updated Sep 25 8:00pm

Add CRMD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CRMD Stock Summary

  • CRMD's price/sales ratio is 929.27; that's higher than the P/S ratio of 99.36% of US stocks.
  • With a year-over-year growth in debt of -99.97%, CorMedix Inc's debt growth rate surpasses only 1.13% of about US stocks.
  • Revenue growth over the past 12 months for CorMedix Inc comes in at -70.77%, a number that bests only 2.12% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CorMedix Inc are PTN, LPCN, INO, RGLS, and MRSN.
  • CRMD's SEC filings can be seen here. And to visit CorMedix Inc's official web site, go to www.cormedix.com.
CRMD Daily Price Range
CRMD 52-Week Price Range

CRMD Stock Price Chart Technical Analysis Charts


CRMD Price/Volume Stats

Current price $5.20 52-week high $7.97
Prev. close $5.23 52-week low $2.16
Day low $5.11 Volume 257,236
Day high $5.31 Avg. volume 344,447
50-day MA $4.77 Dividend yield N/A
200-day MA $5.22 Market Cap 162.44M

CorMedix Inc. (CRMD) Company Bio


CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.


CRMD Latest News Stream


Event/Time News Detail
Loading, please wait...

CRMD Latest Social Stream


Loading social stream, please wait...

View Full CRMD Social Stream

Latest CRMD News From Around the Web

Below are the latest news stories about CorMedix Inc that investors may wish to consider to help them evaluate CRMD as an investment opportunity.

CorMedix rallies; Truits initiates Buy on Defencath under FDA review

Truist initiated CorMedix ([[CRMD]] +12.9%) with a Buy rating, PT $20 indicating a more than four times increase from current levels.In the past 6-months, the stock has surged 96.2%; quick look at the company's total return vs. broader index performance (IYH):Analyst Joon Lee contends that the company's Defencath - which...

Seeking Alpha | September 21, 2020

CorMedix Appoints Paulo Costa to its Board of Directors

Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector

GlobeNewswire | September 17, 2020

CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference taking place on September 14 – 16, 2020.    H.C. Wainwright 22nd Annual Global Investment Conference (virtual) Date:  Monday, September 14 Time:  11:00am Eastern Time Webcast: Link    About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease...

Yahoo | September 9, 2020

NGM Bio Aldafermin Data, And Other News: The Good, Bad And Ugly Of Biopharma

NGM Bio reports positive Phase 2 data for Aldafermin NGM Biopharmaceuticals Inc. (NGM) reported final data from its 24-week Phase 2 study of aldafermin 1 mg. The trial involved patients with non-alcoholic steatohepatitis. The readout included a new analysis of data gathered from Cohort 4 consisting of NASH patients with...

Avisol Capital Partners on Seeking Alpha | September 6, 2020

CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath

* FDA sets PDUFA goal date of February 28, 2021 * Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI). The FDA had previously gr...

Yahoo | August 31, 2020

Read More 'CRMD' Stories Here

CRMD Price Returns

1-mo 7.66%
3-mo -15.72%
6-mo 44.85%
1-year -22.16%
3-year 112.24%
5-year -42.54%
YTD -28.57%
2019 12.87%
2018 158.00%
2017 -67.32%
2016 -24.63%
2015 6.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7289 seconds.